Abdul Aziz Al-Mowani, content manager at MiSK Foundation 

Abdul Aziz Al-Mowani, content manager at MiSK Foundation 
Abdul Aziz Al-Mowani
Short Url
Updated 13 December 2020

Abdul Aziz Al-Mowani, content manager at MiSK Foundation 

Abdul Aziz Al-Mowani, content manager at MiSK Foundation 

Abdul Aziz Al-Mowani has been the content manager at the Prince Mohammed bin Salman Foundation (MiSK) since 2017.

Al-Mowani graduated from King Abdul Aziz University in 2013 with a bachelor’s degree in media.

In 2002, Al-Mowani served as a reporter and editor at the news department for Channel 1 of Saudi Television. He also worked for two years for Rayat Al-Nohoudh, a global advertisement service provider, where he supervised the coordination of conferences and seminars for the company and arranged for direct satellite communications inside and outside the Kingdom.

In 2003, he founded Al-Ekhbariya TV channel as its deputy news director, in addition to being the head of the channel’s TV news exchange department.

In 2008, he also worked as a news anchor on Al-Ekhbariya TV. Three years earlier, he had worked as a field correspondent for MBC for two years.

Between the period from 2008 and 2010, Al-Mowani served as director of operations and deputy CEO at the Arabic Content Co., Saudi Research and Publishing Co. His duties included overseeing production and TV studio as well as coordination with foreign and Arabic TV channels to provide program production and coverage services inside Saudi Arabia. As a production manager, he was responsible for liaising between three companies — the Gulf Digital Media (Tahaluf), the Saudi Research and Marketing Group (SRMG), and the Malaysian All-Asian Satellite Television and Radio Operator (ASTRO).

For two years, beginning from 2010, he founded Line Sports, a Saudi live sports TV channel, specializing in screening both international and local football matches. He was also a member of the channel’s executive board and its production director.

From 2016 to 2017, he worked as Saudi Arabia’s audiovisual manager for Media Gates at Orbit media group. He was responsible for creating and developing Arabic content.


Saudi Arabia’s first COVID-19 vaccine set for clinical trials

Saudi Arabia’s first COVID-19 vaccine set for clinical trials
Updated 18 min 32 sec ago

Saudi Arabia’s first COVID-19 vaccine set for clinical trials

Saudi Arabia’s first COVID-19 vaccine set for clinical trials
  • It will go through rigorous testing and several trial stages before it is approved for use by the Saudi Food and Drug Authority

RIYADH: Preclinical studies on the first Saudi vaccine against COVID-19 have been completed.

Professor of epidemiology Dr. Iman Almansour, who heads the team of researchers working on the vaccine at the Institute for Research and Medical Consultations (IRMC), affiliated with Imam Abdulrahman Bin Faisal University (IAU), confirmed to Arab News on Friday that the studies were complete, and said clinical trials would begin as soon as “the proper approvals” had been given.

She did not specify when that is expected to happen.

The Ministry of Education is financing the team’s project. The team’s research paper has been published in the peer-reviewed journal Pharmaceuticals.

According to the published paper, the vaccine has so far proven effective, when used on animals, in eliciting antibodies that will target the virus. “The vaccine is given to the body to build protein inside cells, which stimulate the body to produce immunity specific to the S antigen,” Dr. Almansour explained.

Dr. Turki Almugaiteeb, director of Healthcare and Life Sciences at RPD Innovations, which runs the National Vaccine and Biomanufacturing Center, told Arab News: “There is a great focus on the results of medical research because of the pandemic. Research can play a great role in developing a vaccine that can be adopted and further developed in the future. We can say that the Kingdom has a strong infrastructure, which can help produce and manufacture a national vaccine.”

Both Almugaiteeb and Almansour stressed that the experimental vaccine will need to go through rigorous testing and several trial stages before it is approved for use by the Saudi Food and Drug Authority.

Prof. Nasser Al-Aqeeli, the deputy minister of education for research and innovation, said the ministry supported programs at the Kingdom’s universities with more than SR500 million ($133.3 million) in 2020.